Massachusetts Financial Services
KROS icon

Massachusetts Financial Services’s Keros Therapeutics KROS Stock Holding History

Massachusetts Financial Services’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$504K Sell
47,121
-1,877
-4% -$20.9K ﹤0.01% 948
2026
Q1 		$541K Buy
48,998
+5,303
+12% +$81.9K ﹤0.01% 894
2025
Q4 		$890K Buy
+43,695
New +$767K ﹤0.01% 837

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Massachusetts Financial Services's KROS Position: Q2 2026 in Review

Massachusetts Financial Services reduced its Keros Therapeutics (KROS) stake by 3.8% in Q2 2026, selling an estimated $20.9K and leaving 47,121 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #948.

Massachusetts Financial Services first reported a position in KROS in Q4 2025 and has held it in 3 quarters since. The position peaked at $890K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Massachusetts Financial Services held 47,121 shares of Keros Therapeutics worth $504K as of Q2 2026.
  • Massachusetts Financial Services sold 1,877 Keros Therapeutics shares in Q2 2026, an estimated $20.9K.
  • Keros Therapeutics made up ﹤0.01% of Massachusetts Financial Services's portfolio in Q2 2026, its #948 holding.
  • Massachusetts Financial Services first reported a position in Keros Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Massachusetts Financial Services's Keros Therapeutics position peaked at $890K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.